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Retroviral vectors derived from amphotropic murine leukemia viruses (MLV) mediate gene transfer into almost all human
cells and are thus not suitable for in vivo applications in gene therapy in which cell-specific gene delivery is required. We and
others recently reported the generation of MLV-derived vectors pseudotyped by variants of the envelope glycoproteins (Env)
of human immunodeficiency virus type 1 (HIV-1), thus displaying the CD4-dependent tropism of the parental lentivirus
(Mammano et al., 1997, J. Virol. 71, 3341–3345; Schnierle et al., 1997, Proc. Natl. Acad. Sci. USA 76, 8640–8645). However,
because of their HIV-1-derived envelopes these vectors are neutralized by HIV-specific antibodies present in some infected
patients. To circumvent this problem, we pseudotyped MLV capsid particles with variants of Env proteins derived from the
apathogenic simian immunodeficiency virus (SIVagm) of African green monkeys (AGM; Chlorocebus pygerythrus). Truncation
of the C-terminal domain of the transmembrane protein was found to be necessary to allow formation of infectious
pseudotype vectors. These [MLV(SIVagm)] vectors efficiently transduced various human CD4-expressing cell lines using the
coreceptors CCR5 and Bonzo to enter target cells. Moreover, they were resistant to neutralization by antibodies directed
against HIV-1. Therefore, [MLV(SIVagm)] vectors will be useful to study the mechanisms of SIVagm cell entry and for the
selective gene transfer into CD41 T-cells of AIDS patients. © 2000 Academic Press
mINTRODUCTION
Selective gene transfer into CD4-expressing human
T-cells is necessary for the treatment of a variety of
immune dysfunctions, including severe combined immu-
nodeficiency (SCID; Anderson, 1984; Blaese et al., 1995)
and AIDS (for review, see Yu et al., 1994; Pomerantz and
Trono, 1995) as well as T-cell lymphomas. Retroviral
vectors derived from murine leukemia virus (MLV) are
suitable for efficient gene transfer into human T-cells,
because they mediate chromosomal integration of the
delivered expression vector and have a low frequency of
genetic recombination or mutation.
In many of the ongoing clinical trials employing retro-
viruses, the retroviral envelopes have been derived from
amphotropic MLV. The surface glycoprotein gp70-SU of
amphotropic MLV, which targets the cell surface receptor
Ram-1 (Kavanaugh et al., 1994; Kozak et al., 1995; Eiden
et al., 1996), allows infection of almost all human primary
cells and is therefore not suitable for gene transfer into a
predetermined cell type. Consequently, gene transfer is
generally performed ex vivo and involves purification of
the target cells, gene transfer in tissue culture, and
reinfusion of the genetically modified cells.
MLV-derived retroviral vectors selective for CD4-posi-
1 tTo whom correspondence and reprint requests should be ad-
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229tive cells have been described previously. We and others
(Mammano et al., 1997; Schnierle et al., 1997)
pseudotyped MLV capsid particles with the envelope
glycoproteins (Env) of human immunodeficiency virus
type 1 [MLV(HIV-1)] (Indraccolo et al., 1998) with those of
the simian immunodeficiency virus from Rhesus ma-
caques (Macaca mulata; [MLV(SIVmac)]). However, the
use of [MLV(HIV-1)] in HIV-seropositive individuals is
hampered by the presence of antibodies directed
against HIV-1 envelope proteins, which are expected to
significantly reduce transduction efficiencies. Although
neutralization of [MLV(SIVmac)] vector particles by HIV-
1-specific antibodies was not studied by Indraccolo et al.
(1998), it is known from previous reports that sera from
HIV-1-infected individuals cross-react with SIVmac
(Blomberg et al., 1990). In contrast, the simian immuno-
deficiency virus (SIVagm) from African green monkeys
(Chlorocebus pygerythrus) is only poorly neutralized by
HIV-1-specific antibodies (Cichutek and Norley, 1993).
Furthermore, while SIVmac is pathogenic not only in its
natural host but also in other primates (Simon et al.,
1994) and humans (Khabbaz et al., 1994), SIVagm is
apathogenic after natural and experimental infection of
African green monkeys and other nonhuman primates
(Beer et al., 1998), making the Env proteins of this virus
ore favorable for the generation of gene-therapy vec-
ors.
The [MLV(HIV-1)] vectors were constructed using the
0042-6822/00 $35.00
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230 STITZ ET AL.surface envelope protein gp120-SU of a T-cell line
adapted HIV-1 variant and a truncated transmembrane
protein (TM; reviewed in Adachi et al., 1986; Wilk et al.,
1992). In contrast, no formation of infectious pseudotype
vectors was observed using the full-length TM-proteins
of HIV-1. Curiously, no C-terminal truncation was reported
to be necessary for SIVmac Env incorporation by MLV
(Indraccolo et al., 1998), pointing out considerable differ-
ences between the envelope glycoproteins of simian and
human immunodeficiency viruses. In addition, Linde-
mann et al. (1997) have reported that fusion of the C-
terminal amino acids of the MLV TM mediated enhanced
incorporation of heterologous envelope glycoproteins
derived from human spuma retrovirus (HSRV) into MLV-
based capsid particles. We therefore wanted to assess
whether these C-terminal regions of MLV TM would also
support the incorporation of envelope glycoproteins de-
rived from SIVagm into the respective vector particles.
The study revealed that truncation of the C-terminal
domain of TM of SIVagm is required for the formation of
infectious pseudotype vectors. The [MLV(SIVagm)] vec-
tors specifically infected CD41 human cells but, in con-
trast to [MLV(HIV-1)] vectors, were resistant to HIV-spe-
cific antibodies or any other inhibiting factor present in
the sera of HIV-1-infected individuals.
RESULTS
Variant env genes of SIVagm are functionally
expressed in TELCeB6/rev cells and mediate
syncytia formation with CD41 T-cells
The wild-type env gene of SIVagm encodes a 130-kDa
FIG. 1. C-terminal amino acid sequences of SIVagm3-TM, MLV TM, an
region (TMR) and of the processed cytoplasmic domains (C-tails) are s
bold indicate amino acid residues encoded by the recombinant NotI-rsurface glycoprotein (gp130-SU) and the transmembrane
glycoprotein gp35-TM. Two env gene variants derivedfrom wild-type SIVagm3mc env (Baier et al., 1990) were
constructed by C-terminal truncation of TM (see Fig. 1).
These variants were designed to encode the full-length
gp135-SU plus a truncated variant of TM, each compris-
ing a C-tail of 10 (D10 env) and 23 (D10MLV env) amino
acids, respectively, following the putative transmem-
brane region (TMR). As a result of the cloning strategy, a
few additional amino acids unrelated to the wild-type TM
were added to the C-termini (see Fig. 1, amino acids in
bold). Env genes D10 env and D10MLV env encode 7
C-terminal amino acids derived from SIVagm and 3 res-
idues generated by a recombinant NotI-restriction site
within the respective env gene variant. In addition,
D10MLV env includes parts of the MLV env gene to
express a chimeric TM-protein terminated by amino ac-
ids derived from MLV TM, which presumably allow con-
tact with the capsid proteins of the MLV core. The HIV-1
rev-positive, but env-negative, packaging cell line TEL-
CeB6/rev constitutively producing capsid particles of
MLV was used for the initial experiments to ensure
sufficient expression of recombinant env gene con-
structs derived from SIVagm. This new packaging cell
line allows efficient expression of rev-negative lentiviral
env genes (data not shown).
TELCeB6/rev cells were transfected with plasmid DNA
comprising the variant SIVagm env genes described
above and cocultivated with Molt4.8 cells. After 3 days,
very large syncytia were seen in cultures containing cells
expressing D10 env, whereas all other cocultures, includ-
ing those with wild-type SIVagm Env-positive cells,
showed only small syncytia (data not shown). All syncytia
observed were specifically stained in the SIVagm-spe-
cific immunoperoxidase assay, indicating that they were
binant TM-proteins. The amino acid sequences of the transmembrane
Sequences derived from MLV are underlined. Larger letters printed in
n sites. All other amino acids are encoded by SIVagm3.d recomformed by expression of fusion-competent env gene
products.
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231[MLV(SIVagm)] TARGETING VECTORSIVagm-derived env gene products encompassing
C-terminally truncated TM allow pseudotype
formation with MLV
To test [MLV(SIVagm)] particle formation and subse-
quent marker gene transfer, the cell line TELCeB6/rev
was transfected with plasmid DNA encoding the respec-
tive SIVagm env gene variants or with plasmid pHIT456
encoding the amphotropic MLV env gene (aMLV env) as
a positive control. Twenty-four hours later, the cells were
cocultivated with 5 3 105 Molt4.8 T-cells in transwell
culture plates, which prevent cell-to-cell contact but al-
low diffusion of vector particles to the target cells. After
a further 2 days, the T-cells were expanded separately
for an additional 2 days, and then X-gal- stained to detect
marker-gene transfer. The transfected packaging cells
were also immunostained to quantify the number of cells
expressing lentiviral envelope glycoproteins to ensure
comparable transfection efficiencies in all experiments.
No gene transfer was detected using the transfected
env gene construct pRepwt env or the negative control
cells (Fig. 2). In contrast, efficient gene transfer was
detectable following transfection of env gene variants
D10 env and D10MLV env, presumably as a result of
nfectious pseudotype particle formation. The number of
ransduced cells, and thus the titer of [MLV(SIVagm)]
articles formed, using D10 Env (650 transduced cells)
as similar to that seen using amphotropic MLV Env
720 transduced cells). Addition of the C-terminal amino
cid sequences of MLV in construct pRepD10MLV env
FIG. 2. Efficacy of pseudotype formation using variant SIVagm env
genes. TELCeB6/rev cells were transiently transfected with the env
genes indicated followed by cocultivation with Molt4.8 T-cells. Mock-
transfected TELCeB6/rev cells served as negative controls; cells trans-
fected with plasmid pHIT456 DNA encoding the env gene of ampho-
tropic MLV (aMLV env) served as positive controls. T-cells were then
stained using the X-gal assay. Transduction efficacies represent the
results of three independent experiments.ed to a decrease in infectious particle formation relative
o that observed using the env gene variant D10 env.MLV(SIVagm)] vector particles specifically infect
D41 cells, efficiently utilizing the coreceptors
CR5 and Bonzo
To establish a packaging cell line continuously pro-
ucing [MLV(SIVagm)] vector particles, plasmid pRepD10
nv, containing in addition to the SIVagm env gene vari-
nt a hygromycin resistance gene, was transfected into
ELCeB6 cells. Following hygromycin B selection, more
han 50 resistant cell colonies were randomly selected
nd shown by immunostaining to express the SIVagm
nv gene. These colonies were pooled and expanded
urther to give the packaging cell line D10Mix. Using
nti-SIVagm serum and a protein G-gold-labeled conju-
ate, labeled vector particles derived from D10Mix cells
ere seen by electron microscopy (data not shown),
ndicating the presence of SIVagm-derived envelope gly-
oproteins. Neither the parental env-negative packaging
ell line TELCeB6 nor TELCeB6 cells transiently trans-
ected with pHIT456 DNA (encoding the amphotropic
LV env gene) produced particles stained with this pro-
edure (data not shown).
These [MLV(SIVagm)] vector stocks harvested from
10Mix packaging cells were employed to transduce the
uman T-cell lines Molt4.8, C8166, and Jurkat as well as
eLa and HeLaCD41 cells. All CD4-positive human
ells were transduced by [MLV(SIVagm)] vector particles
Fig. 3). Titers in Molt4.8 and C8166 cells were 8 and 5 3
04 i.u./ml, respectively. Titers 2–4 were orders of mag-
itude lower in Jurkat and HeLaCD41 cells, while no
transduction of CD4-negative HeLa cells was detected.
To verify that transduction by [MLV(SIVagm)] vector
FIG. 3. Vector titers in various human CD41 cell lines and HeLa
cells. The cell lines indicated were transduced using different dilutions
of a defined vector-containing supernatant derived from packaging cell
line D10Mix. Infection of target cells was determined by X-gal staining
2 days postinfection. Titers shown represent the results of three inde-
pendent experiments. Vector particles harvested from the env-negative
packaging cell line TELCeB6 served as negative controls and were not
able to mediate detectable gene transfer (,10 i.u./ml).
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232 STITZ ET AL.particles was CD4-dependent, transduction experiments
were performed in Molt 4.8 cells in the presence of the
monoclonal anti-CD4 antibody IOT4a, previously shown
to inhibit HIV-1 infection (Sattentau et al., 1986). Target
cells were preincubated for 30 min with the antibody
before [MLV(SIVagm)] vector particles were added. After
2 h, cells were washed and expanded for 3 days.Vector
titers were then measured by X-gal staining. As shown in
Fig. 4A, IOT4a dose-dependent inhibition of transduction
was observed. In contrast, no influence on the gene
transfer efficacy was detectable in the presence of 5
mg/ml of the control antibodies, directed against the
nerve growth factor receptor and CD3, respectively (data
not shown). Entry of the [MLV(SIVagm)] vector particles,
therefore, depends on the presence and availability of
the human CD4 receptor.
To elucidate the coreceptor dependence of the [MLV-
(SIVagm)] vectors, two panels of cell lines (U87 and
GHOST), each expressing human CD4 alone or CD4 plus
FIG. 4. CD4-specificity and coreceptor usage of [MLV(SIVagm)] vec-
tors. (A) Molt4.8 T-cells were incubated in media containing different
concentrations of the anti-CD4 antibody IOT4a and transduced with
[MLV(SIVagm)] vectors. Transduction efficacies shown were deter-
mined using the X-gal assay and resulted from three independent
experiments. (B) A panel of GHOST- and U87-derived cell lines express-
ing different coreceptors and CD4, or only CD4, was transduced by
[MLV(SIVagm)] vectors and infection was revealed by X-gal staining 2
days postinfection. Titers shown represent the means of three inde-
pendent experiments.one of several coreceptors described to allow cell entry
of various HIV and SIV strains, were tested (Hill et al.,
m
i1997; Cecilia et al., 1998). In this investigation, 1 3 105
cells were transduced with various dilutions of [(MLV-
(SIVagm)] vector-containing supernatant harvested from
the packaging cell line D10Mix and vector titers were
measured 2 days later. For both cell panels, the most
efficient transduction was observed with cells express-
ing CD4 and the coreceptor CCR5 (Fig. 4B). GHOST cells
expressing Bonzo were also transduced, however, sig-
nificantly less efficiently. Besides CCR5, the coreceptors
Bob and Bonzo were shown to be used by various other
SIV strains (Deng et al., 1997). It is noteworthy that all
other U87 and GHOST cells, even those expressing only
CD4, showed evidence of low-level transduction. For the
GHOST-cell panel, a low level of Bonzo background ex-
pression was recently demonstrated by Edinger et al.
(1998). As revealed by RT-PCR on RNA extracted from the
U87 cell variants, we could detect Bob- and Bonzo-
specific mRNA (data not shown). Thus, the low level of
background transduction was probably due to Bonzo
expression. Overall, CCR5 and Bonzo are the corecep-
tors used by the [MLV(SIVagm)] vectors. Similar corecep-
tor usage was observed during infection of U87 and
GHOST cells with replication-competent SIVagm3mc
(data not shown).
[MLV(SIVagm)] pseudotype vectors are resistant to
neutralization by sera from HIV-1 infected individuals
SIVagm are only poorly neutralized by anti-HIV-1 anti-
bodies (Cichutek and Norley, 1993) and to test whether
[MLV(SIVagm)] vector particles are also unaffected,
transduction experiments were performed in the pres-
ence of sera from asymptomatic HIV-1-infected donors
previously shown to neutralize various T-cell line
adapted and primary isolates of HIV-1: 5 3 103 i.u. of
MLV(SIVagm)] and of [MLV(HIV-1)] (Stitz et al., 1998)
ere used to transduce Molt4.8 T-cells after incubation
ith the sera (diluted 1:20) for 1 h at 37°C. Two days
ater, as shown in Fig. 5, X-gal staining revealed that the
iters of both pseudotyped vectors were slightly de-
reased by serum from a healthy donor (control serum).
n contrast, anti-HIV-1 sera drastically reduced the titer of
he [MLV(HIV-1)] vector particles, whereas no significant
ffect on the [MLV(SIVagm)] vector was seen.
DISCUSSION
Here we report that the gene products of SIVagm env
ene variants encoding C-tails of 10 and 23 amino acids
nabled formation of infectious [MLV(SIVagm)] vector
articles. In contrast, the wild-type Env of SIVagm, com-
rising 144 C-terminal amino acids, was unable to me-
iate infectivity to MLV capsid particles. Thus, these
esults are in line with our previous findings on the
eneration of [MLV(HIV-1)] pseudotype vectors (Mam-
ano et al., 1997; Schnierle et al., 1997) but are, however,
n contrast to the studies of Indraccolo et al. (1998).
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233[MLV(SIVagm)] TARGETING VECTORCuriously, Indraccolo and his coworkers (1998) de-
scribed comparable vector titers using the unmodified
wild-type and a C-terminally truncated variant of SIVmac
Env protein, respectively. Possibly, the three-dimensional
structure of the C-terminal domain of the SIVmac TM
protein differs from that of the SIVagm and HIV-1 TM
proteins and is therefore more easily incorporated into
the MLV capsid particles. An unexpected finding of our
experiments was that adding the C-terminal amino acids
derived from TM of amphotropic MLV to the truncated
SIVagm TM C-tail did not increase vector titers but even
reduced them about fivefold. From studies on HIV-1 as-
sembly, it is known that contact between the C-tail of Env
and the capsid facilitates incorporation of Env proteins
(Andreassen et al., 1992; Yu et al., 1992; Bugelski et al.,
995; Egan et al., 1996; Lee et al., 1997) and Lindemann
et al. (1997) demonstrated that the fusion of MLV-derived
C-tails to the Env proteins of human spuma retrovirus
(HSRV) significantly enhanced the efficiency of infectious
pseudotype vector formation. It is a matter of speculation
that these contradictory findings might result from differ-
ences in the tertiary structure of HSRV-TM and SIVagm3-
TM. Further constructs need to be tested to resolve this
difference.
Alternatively, the enhanced ability of variant D10 Env to
induce large syncytia as compared to D10MLV Env,
might explain its higher infectivity. The increase of the
fusion ability of lentiviral Env proteins by truncation of the
TM C-terminus was demonstrated before. HIV-1 Env
gene variant Tr712 was used for the production of infec-
tious [MLV(HIV-1)] vector particles (Wilk et al., 1992;
Schnierle et al., 1997). Similarly, Zingler and Littman
FIG. 5. Neutralization of pseudotype vectors by sera from heathy and
HIV-1-infected donors. Pseudotype vectors were incubated with serum
from a healthy (control serum) or five HIV-1-infected donors (HIV 1 to 5)
and then used to transduce Molt4.8 T-cells. Infection was determined
employing the X-gal assay. Transduction efficacies represent the
means of two independent experiments.(1993) observed enhanced infectivity of SIVmac239
pseudotyped with C-terminally truncated Env-variants
t
mcompared to wild-type envelope glycoproteins. In addi-
tion, the increase of the fusion capability of MLV Env by
truncating the C-tails during virion maturation is well
characterized (Rein et al., 1994).
Using the Env variant D10 Env, we established a stable
pseudotype packaging cell line termed D10Mix to gen-
erate [(MLV(SIVagm)] pseudotype vector stocks. The
[MLV(SIVagm)]-pseudotyped vectors allowed efficient
transduction of human T-cells with titers of up to 8 3 104
i.u./ml. In contrast, [MLV(SIVmac)] pseudotype vector
particles (Indraccolo et al., 1998) were described to be
less efficient, yielding maximum titers of 3 3 103 i.u./ml.
More important, and in contrast to [MLV(HIV-1)] vector
particles, the [MLV(SIVagm)] vectors were demonstrated
to be resistant to neutralization by sera from HIV-1-
infected individuals, most likely due to the resistance
against neutralizing HIV-1-specific antibodies.
Transduction mediated by the [MLV(SIVagm)]
pseudotype vectors was shown to be CD4-dependent by
inhibition of vector-mediated gene transfer in the pres-
ence of CD4-specific antibodies. Like SIVagm3mc itself
(data not shown), [MLV(SIVagm)] vector particles were
demonstrated to efficiently use the coreceptors CCR5
and Bonzo. CD4 and CCR5 are expressed on human
primary T-cells and macrophages (Alkhabit et al., 1996;
Deng et al., 1996; Raport et al., 1996; Samson et al., 1996)
and are used by HIV-1 for host cell entry (Alkhabit et al.,
1996; Choe et al., 1996; Dragic et al., 1996; Raport et al.,
1996). Besides macrophages, CD41/CCR51 T-cells are
believed to function as the natural host cell reservoir for
M-tropic HIV-1 strains that are responsible for the initial
infection in humans. Therefore, [MLV(SIVagm)] vector
particles may be useful for transduction of human CD41/
CCR51 T-cells with therapeutic genes encoding HIV-
specific ribozymes, intrabodies, or antisense RNA (Yu et
l., 1994). Efforts will be made to test the new vectors for
heir ability to transduce primary human and primate
D41 cells and to establish more efficient packaging
ells as a prelude to further studies in vivo. In addition,
IVagm Env variants are currently developed to allow the
eneration of [MLV(SIVagm)] vectors specific for CD41/
XCR41 cells. The resistance of such vectors to neu-
ralization by sera from HIV-1-infected donors may make
hem ideal vehicles for specific therapeutic gene transfer
n HIV-1-infected patients, offering new possibilities for in
ivo gene therapy against HIV infection and AIDS.
MATERIALS AND METHODS
lasmid constructs
Plasmids were purified from transformed Escherichia
oli strain Top 10F9. The env gene variants of SIVagm3mc
ere generated using standard PCR and fusion-PCRechniques (Sambrook, 1989) and were inserted into the
ultiple cloning site of plasmid pRep 4 (Invitrogen, Leek,
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234 STITZ ET AL.Netherlands) via NheI/XhoI. Env gene expression is fa-
cilitated by the 39LTR of RSV (Rous sarcoma virus) and a
polyadenylation signal derived from simian virus 40
(SV40). (Primer-sequences are available on request.) The
plasmid pRepwt env encompasses the entire comple-
ment of rev and env genes of SIVagm3mc (Baier et al.,
990; Dittmar et al., 1995). The plasmid pRepD10 env is
identical to pRepwt env, except that the intracellular
domain (C-tail) of the transmembrane protein (TM) is
truncated to a total extent of 10 amino acid residues. This
was achieved by recombinant PCR, inserting a recombi-
nant NotI-restriction site followed by a stop codon. The
plasmid pRepD10MLV env was generated by inserting
sequences encoding parts of the C-tail of MLV into the
recombinant NotI-restriction site. The amino acid se-
quences of the C-tails encoded by the plasmids men-
tioned earlier are shown in Fig. 1. The plasmid pHIT456
encoding the env gene of amphotropic MLV (aMLV env,
indly provided by A. J. Kingsman; University of Oxford,
ambridge, U.K.) has been described elsewhere (So-
eoka et al., 1995).
ell lines
The T-cell lines Molt4.8, C8166 and Jurkat were grown
n RPMI 1640 medium containing 10% fetal calf serum
FCS). The adherent cell lines HeLa, HeLaCD41
ADP047; reviewed in Chesebro et al., 1991), and the
erivatives of U87 and GHOST (both cell line panels
rovided by D. Littmann, New York University Medical
enter, New York; reviewed in Hill et al., 1997; Cecilia et
l., 1998), as well as the packaging cell lines TELCeB6
kindly given by Y. Takeuchi and F.-L. Cosset, Chester
eatty Laboratories, London, U.K., reviewed in Cosset et
l., 1995) and TELCeB6/rev, were grown in Dulbecco’s
odified Eagles Medium (DMEM; GIBCO/BRL, Eggen-
tein, Germany) supplemented with 10% FCS (GIBCO/
RL).
The env-negative packaging cell line TELCeB6 (Cos-
et et al., 1995), providing the gag/pol gene products of
MLV in trans and expressing a c-positive, b-Gal-en-
oding expression vector, was employed to generate
seudotype vector particles, because this cell line
onstitutively releases a large amount of MLV core
articles. The cell line TELCeB6/rev is a cell clone
erived from TELCeB6 cells, which additionally ex-
resses the rev-gene of HIV-1 (construct pCMV-rev/
yg; reviewed in Stitz et al., 1998). Transfections of the
ackaging cell lines TELCeB6/rev and TELCeB6 were
erformed employing Lipofectamine (GIBCO/BRL), ac-
ording to the manufacturer’s instructions. Selection of
ygromycin-resistant colonies after transfection of the
lasmids derived from pRep 4 was carried out in
edium containing 200 mg/ml hygromycin B (Sigma,
eisenhofen, Germany).xpression and membrane fusion capacity of the
IVagm envelope glycoproteins
TELCeB6/rev cells were transfected with the plasmids
ncoding the recombinant env genes of SIVagm3mc. On
he following day, the transfected packaging cells were
verlaid with Molt4.8 T-cells and cocultivated for 2 days.
ultures were then incubated with ice-cold methanol for
5 min. After repeated washing with PBS, blocking buffer
PBS/1% BSA) was added for 1 h. Cells were then
ashed again and incubated with an anti-SIVagm serum
iluted 1:400 (Nem 170). After further washing, cells were
ncubated with peroxidase-conjugated protein-G (Biorad,
refeld, Germany). Finally, antigen-containing cells were
isualized by addition of substrate buffer as described
reviously (Schnierle et al., 1997).
ocultivation experiments
TELCeB6/rev cells were seeded in double-chamber
ix-well tissue culture dishes (Transwell, Costar, Cam-
ridge, MA) and transfected with the respective plas-
ids. Two days posttransfection, Molt4.8 cells were
dded to the upper chamber, allowing the free diffusion
f vector particles but preventing cell-to-cell contact be-
ween the packaging cells and target T-cells. After 2
ays, Molt4.8 cells were separated from the transfected
ackaging cells and expanded for a further 2 days.
ransduced T-cells were then stained using the X-gal
ssay as described elsewhere (Sanes et al., 1986).
iral infection, determination of titers, and
eutralization experiments
Adherent target cells were seeded in six-well culture
ishes at a density of 2 3 105 cells/well and T-cells at
1 3 106 cells/well. Serial dilutions of cell-free (0.45 mm,
filtered) vector containing supernatants were added, in-
cubated for 2 h, and washed off. After 2 days, the cells
were tested for b-Gal activity, stained cells were
ounted, and viral titers expressed as infectious units per
illiliter (i.u./ml). To demonstrate that vector entry into
he target cells was mediated by specific binding of the
seudotype vector particles to the cellular receptor CD4,
ransduction of permissive T-cells was performed in the
resence of the neutralizing (Sattentau et al., 1986) CD4-
pecific monoclonal antibody IOT4a (Dianova, Hamburg,
ermany), antibodies directed against the human nerve
rowth factor receptor (aNGFR; Boehringer, Mannheim,
ermany), and CD3 (OKT-3; OrthoDiagnostics, Germany),
espectively. Susceptibility to neutralization by sera from
IV-1-infected donors was tested byincubating 5 3 103
i.u. vector particles with or without sera (diluted 1:20)
from HIV-1-infected or uninfected donors for 1 h at 37°C
in a total volume of 1 ml. Samples were then used to
transduce Molt4.8 T-cells as described. Vector titers
were estimated after X-gal staining of transduced cells.
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235[MLV(SIVagm)] TARGETING VECTORElectron microscopy
Confluent cultures of the packaging cell lines were
treated with fixation buffer (PBS/2% formaldehyde) for 1 h
at 4°C, repeatedly washed with PBS, and finally incu-
bated with 1:100 dilutions of anti-SIVagm serum (Nem
170) for 1 h at 37°C. After further washing, a 1:50 dilution
of gold particle-conjugated protein-G (Bio Cell, Cardiff,
U.K.) was added and left for 1 h at 37°C. After extensive
washing with PBS, cells were embedded in epoxyd ac-
cording to standard procedures (Luft, 1964).
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